Stress-inducible gene Atf3 in the noncancer host cells contributes to chemotherapy-exacerbated breast cancer metastasis

Significance Chemotherapy is a double-edged sword. It is anticancer because of its cytotoxicity. Paradoxically, by increasing chemoresistance and cancer metastasis, it is also pro-cancer. However, the mechanisms underlying chemotherapy-induced procancer activities are not well understood. Here we present data that provide mechanistic explanations for the ability of paclitaxel (PTX), a frontline chemotherapeutic agent, to exacerbate metastasis in mouse models of breast cancer. Importantly, Atf3, a stress-inducible gene, in the noncancer host cells is necessary for this PTX effect. Analyses of publicly available datasets suggest that our data from mouse models have relevance to human cancers. Thus, ATF3 links a chemotherapeutic agent—a stressor—to pro-metastatic changes in the host cells. Dampening the effect of ATF3 may improve the efficacy of chemotherapy. Chemotherapy is a double-edged sword. It is anticancer because of its cytotoxicity. Paradoxically, by increasing chemoresistance and cancer metastasis, it is also procancer. However, the underlying mechanisms for chemotherapy-induced procancer activities are not well understood. Here we describe the ability of paclitaxel (PTX), a frontline chemotherapeutic agent, to exacerbate metastasis in mouse models of breast cancer. We demonstrate that, despite the apparent benefit of reducing tumor size, PTX increased the circulating tumor cells in the blood and enhanced the metastatic burden at the lung. At the primary tumor, PTX increased the abundance of the tumor microenvironment of metastasis, a landmark microanatomical structure at the microvasculature where cancer cells enter the blood stream. At the metastatic lung, PTX improved the tissue microenvironment (the “soil”) for cancer cells (the “seeds”) to thrive; these changes include increased inflammatory monocytes and reduced cytotoxicity. Importantly, these changes in the primary tumor and the metastatic lung were all dependent on Atf3, a stress-inducible gene, in the noncancer host cells. Together, our data provide mechanistic insights into the procancer effect of chemotherapy, explaining its paradox in the context of the seed-and-soil theory. Analyses of public datasets suggest that our data may have relevance to human cancers. Thus, ATF3 in the host cells links a chemotherapeutic agent—a stressor—to immune modulation and cancer metastasis. Dampening the effect of ATF3 may improve the efficacy of chemotherapy.

[1]  Mei Liu,et al.  Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Y. Shaked Balancing efficacy of and host immune responses to cancer therapy: the yin and yang effects , 2016, Nature Reviews Clinical Oncology.

[3]  Jindan Yu,et al.  The common stress responsive transcription factor ATF3 binds genomic sites enriched with p300 and H3K27ac for transcriptional regulation , 2016, BMC Genomics.

[4]  I. Keklikoglou,et al.  Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy. , 2015, Cancer research.

[5]  Yarong Wang,et al.  Real-Time Imaging Reveals Local, Transient Vascular Permeability, and Tumor Cell Intravasation Stimulated by TIE2hi Macrophage-Derived VEGFA. , 2015, Cancer discovery.

[6]  J. Bergh,et al.  Gene expression profiling of sequential metastatic biopsies for biomarker discovery in breast cancer , 2015, Molecular oncology.

[7]  S. Ran The Role of TLR4 in Chemotherapy-Driven Metastasis. , 2015, Cancer research.

[8]  Brian Ruffell,et al.  Macrophages and therapeutic resistance in cancer. , 2015, Cancer cell.

[9]  Vivien W. Chan,et al.  Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. , 2014, Cancer cell.

[10]  S. Ran,et al.  Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner. , 2014, Cancer research.

[11]  T. Rohan,et al.  Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer. , 2014, Journal of the National Cancer Institute.

[12]  Jeffrey W Pollard,et al.  Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.

[13]  D. Munn,et al.  Immunosuppressive myeloid cells induced by chemotherapy attenuate antitumor CD4+ T-cell responses through the PD-1-PD-L1 axis. , 2014, Cancer research.

[14]  S. Stacker,et al.  Lymphangiogenesis and lymphatic vessel remodelling in cancer , 2014, Nature Reviews Cancer.

[15]  D. Linehan,et al.  Targeting tumor-infiltrating macrophages to combat cancer. , 2013, Immunotherapy.

[16]  J. Condeelis,et al.  Macrophage contact induces RhoA GTPase signaling to trigger tumor cell intravasation , 2013, Oncogene.

[17]  Michael C. Ostrowski,et al.  Transcription factor ATF3 links host adaptive response to breast cancer metastasis. , 2013, The Journal of clinical investigation.

[18]  Jonathan B. Mitchem,et al.  Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis , 2013, Clinical Cancer Research.

[19]  C. Lewis,et al.  Macrophage regulation of tumor responses to anticancer therapies. , 2013, Cancer cell.

[20]  Jonathan B. Mitchem,et al.  Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. , 2013, Cancer research.

[21]  Wilfrid Boireau,et al.  Chemotherapy-triggered cathepsin B release in myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes tumor growth , 2012, Nature Medicine.

[22]  Sangdun Choi,et al.  Doxorubicin Induces Cytotoxicity through Upregulation of pERK–Dependent ATF3 , 2012, PloS one.

[23]  Raymond K. Auerbach,et al.  An Integrated Encyclopedia of DNA Elements in the Human Genome , 2012, Nature.

[24]  Z. Werb,et al.  Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance. , 2012, Cancer cell.

[25]  L. Coussens,et al.  Immune microenvironments in solid tumors: new targets for therapy. , 2011, Genes & development.

[26]  E. Brogi,et al.  Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer. , 2011, Genes & development.

[27]  E. Voest,et al.  Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells. , 2011, Cancer research.

[28]  T. Voloshin,et al.  Host response to short-term, single-agent chemotherapy induces matrix metalloproteinase-9 expression and accelerates metastasis in mice. , 2011, Cancer research.

[29]  Robert A. Weinberg,et al.  Tumor Metastasis: Molecular Insights and Evolving Paradigms , 2011, Cell.

[30]  L. Elia,et al.  A Cell-Based High-Content Screening Assay Reveals Activators and Inhibitors of Cancer Cell Invasion , 2011, Science Signaling.

[31]  Hideaki Tahara,et al.  Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells , 2011, Proceedings of the National Academy of Sciences.

[32]  Luke A. Gilbert,et al.  Chemotherapeutic resistance: surviving stressful situations. , 2011, Cancer research.

[33]  Jinghang Zhang,et al.  CCL2 recruits inflammatory monocytes to facilitate breast tumor metastasis , 2011, Nature.

[34]  Karin Jirström,et al.  Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. , 2011, Cancer discovery.

[35]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[36]  R. Kerbel,et al.  Cancer: Chemotherapy counteracted , 2010, Nature.

[37]  R. Young,et al.  Histone H3K27ac separates active from poised enhancers and predicts developmental state , 2010, Proceedings of the National Academy of Sciences.

[38]  Luke A. Gilbert,et al.  DNA Damage-Mediated Induction of a Chemoresistant Niche , 2010, Cell.

[39]  Tsonwin Hai,et al.  Cisplatin induces cytotoxicity through the mitogen-activated protein kinase pathways and activating transcription factor 3. , 2010, Neoplasia.

[40]  Tsonwin Hai,et al.  ATF3, a hub of the cellular adaptive-response network, in the pathogenesis of diseases: is modulation of inflammation a unifying component? , 2010, Gene expression.

[41]  Philip S Rosenberg,et al.  Male breast cancer: a population-based comparison with female breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  Ruth J. Muschel,et al.  A Distinct Macrophage Population Mediates Metastatic Breast Cancer Cell Extravasation, Establishment and Growth , 2009, PloS one.

[43]  John S. Condeelis,et al.  Tumor Microenvironment of Metastasis in Human Breast Carcinoma: A Potential Prognostic Marker Linked to Hematogenous Dissemination , 2009, Clinical Cancer Research.

[44]  A. Visel,et al.  ChIP-seq accurately predicts tissue-specific activity of enhancers , 2009, Nature.

[45]  A. C. Wang,et al.  Role of TLR4 for paclitaxel chemotherapy in human epithelial ovarian cancer cells , 2009, European journal of clinical investigation.

[46]  R. Kerbel,et al.  Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. , 2008, Cancer cell.

[47]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[48]  S. I. Park,et al.  Role of Activating Transcription Factor 3 on TAp73 Stability and Apoptosis in Paclitaxel-Treated Cervical Cancer Cells , 2008, Molecular Cancer Research.

[49]  John N Weinstein,et al.  A stromal gene signature associated with inflammatory breast cancer , 2008, International journal of cancer.

[50]  Tsonwin Hai,et al.  A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development , 2007, Oncogene.

[51]  Frank Rose,et al.  Metastasis: the seed and soil theory gains identity , 2007, Cancer and Metastasis Reviews.

[52]  J. Segall,et al.  Coordinated regulation of pathways for enhanced cell motility and chemotaxis is conserved in rat and mouse mammary tumors. , 2007, Cancer research.

[53]  L. Coussens,et al.  Humoral immunity, inflammation and cancer. , 2007, Current opinion in immunology.

[54]  Yarong Wang,et al.  Direct visualization of macrophage-assisted tumor cell intravasation in mammary tumors. , 2007, Cancer research.

[55]  E. Stanley,et al.  Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts. , 2006, Cancer research.

[56]  Tsonwin Hai,et al.  Activating Transcription Factor 3, a Stress-inducible Gene, Suppresses Ras-stimulated Tumorigenesis* , 2006, Journal of Biological Chemistry.

[57]  M. Mottolese,et al.  The Cytoskeleton Regulatory Protein hMena (ENAH) Is Overexpressed in Human Benign Breast Lesions with High Risk of Transformation and Human Epidermal Growth Factor Receptor-2–Positive/Hormonal Receptor–Negative Tumors , 2006, Clinical Cancer Research.

[58]  S. Rafii,et al.  VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.

[59]  Luigi Naldini,et al.  Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. , 2005, Cancer cell.

[60]  John S. Condeelis,et al.  Identification and Testing of a Gene Expression Signature of Invasive Carcinoma Cells within Primary Mammary Tumors , 2004, Cancer Research.

[61]  Steffen Jung,et al.  Blood monocytes consist of two principal subsets with distinct migratory properties. , 2003, Immunity.

[62]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[63]  M. Barry,et al.  Cytotoxic T lymphocytes: all roads lead to death , 2002, Nature Reviews Immunology.

[64]  Tsonwin Hai,et al.  The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. , 2001, Gene.

[65]  L. Saltz,et al.  New therapies, new directions: advances in the systemic treatment of metastatic colorectal cancer. , 2001, The Lancet. Oncology.

[66]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[67]  A. Pileri,et al.  Clinical relevance of minimal residual disease monitoring in non-Hodgkin’s lymphomas: a critical reappraisal of molecular strategies , 1999, Leukemia.

[68]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[69]  Akiko Sakai,et al.  Comparative proteomic analysis of paclitaxel resistance-related proteins in human breast cancer cell lines. , 2017, Oncology letters.

[70]  Tsonwin Hai,et al.  Immunohistochemical detection of activating transcription factor 3, a hub of the cellular adaptive-response network. , 2011, Methods in enzymology.

[71]  G. Hortobagyi,et al.  Overview of resistance to systemic therapy in patients with breast cancer. , 2007, Advances in experimental medicine and biology.

[72]  J. Gregg,et al.  Syngeneic mouse mammary carcinoma cell lines: Two closely related cell lines with divergent metastatic behavior , 2005, Clinical & Experimental Metastasis.

[73]  R. Dickson,et al.  Explant-cell culture of primary mammary tumors from MMTV-c-Myc transgenic mice , 2004, In Vitro Cellular & Developmental Biology - Animal.

[74]  Tsonwin Hai,et al.  ATF3 and stress responses. , 1999, Gene expression.

[75]  J. Beijnen,et al.  Preclinical pharmacokinetics of paclitaxel and docetaxel. , 1998, Anti-cancer drugs.

[76]  M. Montminy,et al.  Transcriptional regulation by cyclic AMP. , 1997, Annual review of biochemistry.